ChemT Biotechnology Raises $5 Million to Advance AI-Powered Biomanufacturing
ChemT Biotechnology, an AI-powered biotechnology company, has raised $5 million over the past 18 months, including a $4 million seed funding round led by Wavemaker Ventures with participation from SEEDS. The funding will support the development of the company's AI-powered technologies designed to address critical challenges in biologics and cell therapy manufacturing.
Based in the United States and Singapore, ChemT develops solutions that help biopharmaceutical companies and Contract Development and Manufacturing Organizations (CDMOs) accelerate development and commercial production while improving manufacturing efficiency, product quality, and productivity.
Large-scale biologics manufacturing remains one of the industry's biggest challenges, as companies often struggle to maintain efficiency and product quality when scaling from laboratory research to commercial production. Manufacturers frequently face lengthy development cycles, inconsistent production outcomes, and lower yields, with processes that perform well in early-stage research often proving difficult to scale.
To overcome these challenges, ChemT combines machine learning with laboratory experimentation to develop AI-designed small molecules that optimize the behavior of cells used in biomanufacturing. The company's technology is designed to improve production efficiency, increase yields, and deliver more consistent manufacturing performance.
Jay Son, Co-founder and CEO of ChemT Biotechnology, said:
"Within just about a year and a half of launching, ChemT has established commercial partnerships with more than 40 pharmaceutical companies, biotechnology firms, and contract manufacturers worldwide. The future of biomanufacturing will not rely on automation alone, but on intelligence that can optimize processes and support better decision-making."
Founded in 2024 by Dr. Ling Wu and Jay Son, ChemT Biotechnology combines expertise in biopharmaceuticals, artificial intelligence, and entrepreneurship to develop AI-designed small molecules that make biologics manufacturing more efficient and reliable.
The company's flagship AI-developed small-molecule compound has demonstrated the ability to increase production yields by five to ten times while simultaneously improving the quality of final products. The technology has also shown promising results in laboratory and animal studies, reinforcing its potential for future commercial applications in the biopharmaceutical sector.
Paul Santos, Co-founder and Managing Partner at Wavemaker Partners, said:
"Biomanufacturing has long faced structural challenges that have limited its progress. ChemT's technology offers a new approach to enhancing the performance of cells used in biologics production, enabling faster, more cost-effective, and more stable manufacturing processes."
He added that the company combines advanced computational capabilities, laboratory expertise, and market access, creating a combination that is relatively rare among life sciences startups.
The investment comes amid growing interest in AI-powered technologies that enhance biotechnology research, development, and manufacturing. Through expanding its commercial partnerships and advancing its technology platform, ChemT Biotechnology aims to play a greater role in supporting the next generation of biologics and cell therapy manufacturing worldwide.
